Amicus Therapeutics, Inc.
- FOLD
- NASDAQ
- Biotechnology
- Rare Disease Biotech
- Fabry Disease Treatment
$14.49
Quote Apr 27, 2026, 08:00 PM UTC
+0.42%over the last month
Max drawdown −0.1%From 1-month high 0.0%3 months +1.4%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Amicus Therapeutics
Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery, development, and delivery of medical treatments for rare conditions. Its primary commercial offering is Galafold, an orally administered precision medicine designed for adult patients with a confirmed diagnosis of Fabry disease, specifically those exhibiting an amenable galactosidase alpha gene variant as identified by in vitro assay data.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
499
Founded
2002
Market value
$4.55B
Quote Apr 27
Floor
$14.34
1.1% below price
Resistance
$14.50
0.0% above price
Price vs analyst targets
24 analysts
Lowest target
$13.00Highest target
$19.00
$13.00Highest target
$19.00
- Price $14.49
- Average target $14.86
- Analysts' target range
Analysts' average target sits about 3% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about FOLDPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free